摘要
目的探讨放射性125I粒子联合化疗治疗中、晚期肺癌的疗效及安全性评估。方法 53例肺癌患者应用CT引导经皮穿刺植入125I粒子联合化疗治疗,监测治疗前、第2次和第4次化疗后血清癌胚抗原、神经特异性烯醇化酶、细胞角蛋白19片段水平变化,同时行CT等检查。结果治疗后腺癌患者血清癌胚抗原水平、小细胞肺癌患者血清神经特异性烯醇化酶水平、鳞癌患者血清细胞角蛋白19片段水平均较治疗前明显下降,差异有统计学意义(P<0.05)。治疗后完全缓解率15.09%,部分缓解率为77.36%,无变化5.66%,进展1.89%,近期有效率92.45%。结论 125I粒子植入联合化疗是治疗中、晚期肺癌的有效方法。
Objective To observate the effect of radioactive 125 I seeds implantation combined with chemotherapy on advanced lung cancer and to evaluate its safety. Methods Fifty-three patients with lung cancer underwent CT-guided 125I seeds implantation combined with chemotherapy. The serum carcinoembryonie antigen, neuron-specific enolase and cytokeratins 21-1 were detected and CT follow-up were performed before treatment, after twice and four times of chemotherapy. Results After treatment, carcinoembryonic antigen level was lower in adenocarcinoma, cytokeratins 21-1 level was lower in squamous cell carcinoma and neuron-specific enolase level was lower in small cell carcinoma, which showed a significant difference in comparison with that before treatment（P~ 0.05）. The complete remissio：- rate was 15.09%, the partial remission rate was 77.36%, the no change rate was 5.66%0, and the progressive disease rate was 1.89%. The recent effective rate was 92.45M. Conclusion 125I seeds implantation combined with chemotherapy is an effective method for advanced lung cancer.
出处
《中华实用诊断与治疗杂志》
2012年第3期257-259,共3页
Journal of Chinese Practical Diagnosis and Therapy
关键词
肺癌
放射性125I
化疗
肿瘤标志物
植入
Lung cancer
radioactive 125I
chemotherapy
tumor markers
implantation
作者简介
王猛（1986-），男，在读硕士研究生，研究方向：肿瘤微创治疗。
周志刚（1966-），男，硕士，主任医师，研究方向：肿瘤微创治疗，Email：hnzzgl26@126．com。
